Table II.

Polymer-Based Nanomedicines under Clinical Evaluation for Use in Cancer Therapy

Name (company)	Particle type and drug	Investigated indication	Clinical phase	Identifiera
AZD2811 (AstraZeneca with BIND Therapeutics)	Aurora B kinase inhibitor in BIND therapeutics polymer particle accurin platform	Advanced solid tumors	Ph I	NCT02579226
BIND-014 (BIND Therapeutics)	PSMA targeted (via ACUPA) docetaxel PEG-PLGA or PLAPEG particle	Prostate, metastatic, nonsmall cell lung, cervical, head and neck, or KRAS positive lung cancers	Ph II; Ph II; Ph II; Ph II; Ph I	NCT02479178; NCT02283320; NCT01812746; NCT01792479; NCT01300533
Cynviloq IG-001 (Sorrento)	Paclitaxel polymeric micelle nanoparticle	Breast cancer	Not provided	NCT02064829
Genexol-PM (Samyang Biopharmaceuticals)	Paclitaxel polymeric micelle nanoparticle	Head and neck or breast cancer	Ph II; Ph II; Ph IV	NCT01689194; NCT02263495; NCT00912639
NC-6004 Nanoplatin (Nanocarrier)	Polyamino acid, PEG, and cisplatin derivative micellar nanoparticle	Advanced solid tumors, lung, biliary, bladder, or pancreatic cancers	Ph I/II; Ph III	NCT02240238; NCT02043288
NC-4016 DACH-Platin Micelle (Nanocarrier)	Polyamino acid, PEG, and oxaliplatin micellar nanoparticle	Advanced solid tumors or lymphomas	Ph I	NCT01999491
NK105 (Nippon Kayaku)	Paclitaxel micelle	Breast cancer	Ph III	NCT01644890
Docetaxel-PM DOPNP201 (Samyang Biopharmaceuticals)	Docetaxel micelle	Head and neck cancer and advanced solid tumors	Ph II; Ph I	NCT02639858; NCT02274610
CriPec (Cristal Therapeutics)	Docetaxel micelles	Solid tumors	Ph I	NCT02442531
CRLX101 (Cerulean)	Cyclodextrin based nanoparticlecamptothecin conjugate	Ovarian, renal cell, small cell lung, or rectal cancers	Ph II; Ph I/II; Ph I; Ph II; Ph II	NCT02187302; NCT02010567; NCT02389985; NCT01803269; NCT01652079
CRLX301 (Cerulean)	Cyclodextrin based nanoparticle-docetaxel conjugate	Dose escalation study in advanced solid tumors	Ph I/II	NCT02380677

Adapted from Ref. 26, with permission from Wiley.

^aFrom ClinicalTrials.gov.